Vaccination against human papillomavirus

被引：2

作者：

Hillemanns, Peter ^{[1
]}

Kampers, Johanna ^{[1
]}

Hachenberg, Jens ^{[1
]}

Jentschke, Matthias ^{[1
]}

机构：

[1] Med Hsch Hannover MHH, Klin Frauenheilkunde & Geburtshilfe, Carl Neuberg Str 1, D-30625 Hannover, Germany

来源：

INTERNIST | 2021年 / 62卷 / 08期

关键词：

Uterine cervical neoplasms; Uterine cervical dysplasia; Cervical intraepithelial neoplasia; Immunization coverage; Prevention; PARTICLE VACCINE; HPV-VACCINATION; YOUNG-WOMEN; EFFICACY; NEOPLASIA; TYPE-16;

D O I：

10.1007/s00108-021-01102-0

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Vaccination against human papillomavirus (HPV), which has been proven to be highly effective and safe, is recommended as part of standard vaccination by the German Standing Committee on Vaccination (STIKO) for 9- to 14-year-old girls and boys. Up to 90% of cervical cancer and its precancerous lesions can be prevented with timely vaccination (before first intercourse). In addition, the effectiveness extends to the primary prevention of HPV-associated neoplasms of the vulva, vagina, anus, penis and oropharynx. The HPV vaccination is the focus of the global initiative of the WHO calling on German health policymakers to significantly increase the immunization coverage of the German population, which is currently only 45-60%. Due to the high immunogenicity and the convincing long-term effects, the goals of eliminating cervical cancer and significantly reducing other HPV-associated cancers are theoretically achievable.

引用

页码：816 / 826

页数：11

共 35 条

[1] Decline in in-patient treatments of genital warts among young Australians following the national HPV vaccination program [J].